Direct Investments

Significant contract for OXGENE

Mercia Asset Management PLC is pleased to confirm that its portfolio company OXGENE, formally known as Oxford Genetics, has augmented its relationship with one of the world’s leading global life science companies, Abcam plc. 

Dr Mark Payton, CEO of Mercia Asset Management PLC and non-executive director of OXGENE said, “OXGENE epitomises a truly disruptive approach and is building an impressive reputation with numerous commercial partnerships such as the one with Abcam. We have backed the company since the very start and are delighted to be involved in their journey as they continue to grow their position in the global multi-billion-dollar life sciences market.”

You can read the full RNS Reach here.